Autopsy report · NCT06630325

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

“Loss of support.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 9 months before it started.
• Ran for about 9 months before it stopped.
• 6 participants enrolled.
• Results were posted on the registry 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

OHSU Knight Cancer Institute

Sponsor type

University, hospital or other

Conditions

Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma

Interventions

Abemaciclib; Biopsy; Bone Scan; Echocardiography; Exemestane; Gemcitabine

Participants

6

Sites

1

Countries

United States

Trials that died the same way

• The Impact of an Online Stress Management Program on In Vitro Fertilization (IVF) Outcome
  “Loss of funding.” (70% match in meaning)
• Safety of Navoximod and NLG802 With Stereotactic Body Radiotherapy (SBRT) Treatment of Advanced Solid Tumors
  “Lack of funding support.” (65% match in meaning)
• Efficacy of Pramipexole Extended Release in the Treatment of Essential Tremor
  “Lack of financial support” (62% match in meaning)
• 18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma
  “loss of sponsor support” (61% match in meaning)
• Impact of Surgical Theater's Patient Engagement
  “Lack of support/funding” (61% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.